Myomo, Inc.
MYOMyomo, Inc. in brief
Myomo, Inc. is a listed company in the Medical Devices industry, based in Boston, Massachusetts, USA. Its market value was $47 M on 28 October 2026, which makes it the 21,515th largest listed company in the world and the 3,886th largest in the USA on this site. In the year to December 2025 it had sales of $41 M and a net loss of $16 M. Paul R. Gudonis is its chief executive. Its shares trade under the symbol MYO (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Myomo, Inc.
We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. We primarily provide devices directly to patients and bill their insurance companies directly, a sales channel we refer to as direct billing. Under direct billing, we evaluate, measure and fit the MyoPro devices using our own clinical staff or as circumstances dictate, utilize the clinical consulting services of orthotics and prosthetics, or O&P. We also sell our products through various other sales channels, including through O&P providers, which we expect to be a larger contributor to revenue in the future, the Veterans Administration, or VA, and to certain accounts and geographic markets outside the United States. We operate as one business segment.
From the company's annual report filed with the US SEC: read the report
Myomo, Inc. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔· approximateInitial public offering on NYSE
- 2025
- 💰Record revenue of $41 millionFY2025, the highest of the 8 years on record.
Events of Myomo, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,920 (Jan 2022) · #5,847 (Dec 2022) · #5,293 (Jul 2023) · #3,607 (Jan 2024) · #2,243 (Mar 2026) · #3,618 (Aug 2026) · #3,772 (Oct 2026) · #3,890 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.0×
- Price / book
- 4.1×
- Free cash flow yield
- -34.6%
- Net margin (TTM)
- -33.1%
- Operating margin
- -35.2%
- Return on equity
- -132.2%
- Liabilities / assets
- 70.5%
- Net debt
- $-3M
- Revenue growth
- +25.7%
- R&D / revenue
- 17.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $41M | +25.7% | $-14M | $-16M | -38.0% |
| Dec 2024 | $33M | +69.2% | $-6M | $-6M | -19.0% |
| Dec 2023 | $19M | +23.7% | $-8M | $-8M | -42.4% |
| Dec 2022 | $16M | +12.3% | $-11M | $-11M | -68.9% |
| Dec 2021 | $14M | +82.8% | $-10M | $-10M | -74.8% |
| Dec 2020 | $8M | +97.4% | $-11M | $-12M | -152.5% |
| Dec 2019 | $4M | +57.4% | $-11M | $-11M | -278.9% |
| Dec 2018 | $2M | — | $-11M | $-10M | -423.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-15M | $2M | $-16M | $-0.37 | — |
| Dec 2024 | $-3M | $1M | $-5M | $-0.16 | — |
| Dec 2023 | $-6M | $0M | $-6M | $-0.28 | — |
| Dec 2022 | $-10M | $0M | $-10M | $-1.52 | — |
| Dec 2021 | $-10M | $0M | $-10M | $-1.89 | — |
| Dec 2020 | $-9M | $0M | $-9M | $-3.67 | — |
| Dec 2019 | $-10M | $0M | $-10M | $-20.79 | — |
| Dec 2018 | $-10M | $0M | $-10M | $-25.18 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $12M (+22.2% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Jun 29, 20268-K/ACurrent report (amended)Directors or officers changed · Bylaws amended · Shareholder vote
- Jun 26, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- May 14, 2026DEF 14AProxy statement
- May 13, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 29, 202610-K/AAnnual report (amended) · period to Dec 2025
- Apr 16, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
Official filings of Myomo, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $41 M
- Operating income
- $-14 M
- Net income
- $-16 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $39 M
- Total liabilities
- $27 M
- Total equity
- $11 M
As of December-2025
Top 66 institutional investors in Myomo, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 3,917,886 | +280,000 (+7.70%) | 9.77% | $6 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 1,636,570 | 0 (0.00%) | 4.08% | $3 M | Nov 13, 2026 |
| 3 | Clearstead Advisors, LLC | 425,600 | -9 (0.00%) | 1.06% | $1 M | Nov 6, 2026 |
| 4 | Two Sigma Investments, LP | 388,107 | New | 0.97% | $1 M | Nov 16, 2026 |
| 5 | Jane Street Group, LLC | 380,802 | -215,550 (-36.14%) | 0.95% | $1 M | Nov 12, 2026 |
| 6 | Geode Capital Management, LLC | 350,490 | +6,073 (+1.76%) | 0.87% | $1 M | Nov 6, 2026 |
| 7 | Morgan Stanley | 330,944 | +324,320 (+4896.14%) | 0.83% | $1 M | Nov 13, 2026 |
| 8 | Palumbo Wealth Management LLC | 278,354 | -21,422 (-7.15%) | 0.69% | $0 M | Nov 13, 2026 |
| 9 | Gsa Capital Partners LLP | 252,663 | -19,213 (-7.07%) | 0.63% | $0 M | Nov 16, 2026 |
| 10 | Millennium Management LLC | 247,380 | -23,914 (-8.81%) | 0.62% | $0 M | Nov 16, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 246,139 | +38,462 (+18.52%) | 0.61% | $0 M | Nov 13, 2026 |
| 12 | Marshall Wace, LLP | 222,755 | New | 0.56% | $0 M | Nov 13, 2026 |
| 13 | AQR Capital Management LLC | 207,782 | -720,486 (-77.62%) | 0.52% | $0 M | Nov 16, 2026 |
| 14 | Arrowstreet Capital, Limited Partnership | 180,629 | New | 0.45% | $0 M | Nov 13, 2026 |
| 15 | LPL Financial LLC | 153,100 | -154,900 (-50.29%) | 0.38% | $0 M | Nov 6, 2026 |
| 16 | BlackRock, Inc. | 136,261 | -86,956 (-38.96%) | 0.34% | $0 M | Nov 13, 2026 |
| 17 | Citadel Advisors LLC | 109,786 | +7,268 (+7.09%) | 0.27% | $0 M | Nov 16, 2026 |
| 18 | Centiva Capital, LP | 108,606 | +22,610 (+26.29%) | 0.27% | $0 M | Nov 13, 2026 |
| 19 | State Street Corp | 105,875 | 0 (0.00%) | 0.26% | $0 M | Nov 12, 2026 |
| 20 | Renaissance Technologies LLC | 101,700 | +53,200 (+109.69%) | 0.25% | $0 M | Nov 12, 2026 |
| 21 | Northern Trust Corp | 80,609 | 0 (0.00%) | 0.20% | $0 M | Nov 16, 2026 |
| 22 | Acadian Asset Management LLC | 74,392 | New | 0.19% | $0 M | Nov 9, 2026 |
| 23 | XTX Topco Ltd | 68,600 | -41,428 (-37.65%) | 0.17% | $0 M | Nov 16, 2026 |
| 24 | Stratos Wealth Partners, LTD. | 60,000 | 0 (0.00%) | 0.15% | $0 M | Nov 13, 2026 |
| 25 | Quadrature Capital Ltd | 57,956 | New | 0.14% | $0 M | Nov 13, 2026 |
Show all 66: investors 26 to 66
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Goldman Sachs Group Inc | 56,830 | -38,018 (-40.08%) | 0.14% | $0 M | Nov 16, 2026 |
| 27 | Bridgeway Capital Management, LLC | 42,519 | New | 0.11% | $0 M | Nov 16, 2026 |
| 28 | Empowered Funds, LLC | 39,619 | New | 0.10% | $0 M | Nov 13, 2026 |
| 29 | Accel Wealth Management | 39,082 | 0 (0.00%) | 0.10% | $0 M | Oct 13, 2026 |
| 30 | FMR LLC | 28,638 | -971 (-3.28%) | 0.07% | $0 M | Nov 10, 2026 |
| 31 | IMC-Chicago, LLC | 26,328 | +5,854 (+28.59%) | 0.07% | $0 M | Nov 5, 2026 |
| 32 | Summit Financial Strategies, Inc. | 25,000 | 0 (0.00%) | 0.06% | $0 M | Oct 14, 2026 |
| 33 | Accurate Wealth Management, LLC | 21,120 | 0 (0.00%) | 0.05% | $0 M | Oct 20, 2026 |
| 34 | Cerity Partners LLC | 19,418 | -25,880 (-57.13%) | 0.05% | $0 M | Nov 13, 2026 |
| 35 | Ieq Capital, LLC | 16,725 | -111,024 (-86.91%) | 0.04% | $0 M | Nov 10, 2026 |
| 36 | Qube Research & Technologies Ltd | 14,202 | -53,562 (-79.04%) | 0.04% | $0 M | Nov 13, 2026 |
| 37 | Abel Hall, LLC | 12,927 | -337 (-2.54%) | 0.03% | $0 M | Oct 19, 2026 |
| 38 | StoneX Group Inc. | 11,842 | New | 0.03% | $0 M | Nov 3, 2026 |
| 39 | Prudential Financial Inc | 11,400 | New | 0.03% | $0 M | Nov 16, 2026 |
| 40 | Vanguard Global Advisers, LLC | 10,870 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 41 | Jpmorgan Chase & Co | 9,888 | -18,842 (-65.58%) | 0.02% | $0 M | Nov 12, 2026 |
| 42 | UBS Group AG | 7,090 | -406,589 (-98.29%) | 0.02% | $0 M | Nov 10, 2026 |
| 43 | Arax Advisory Partners | 5,710 | -10,884 (-65.59%) | 0.01% | $0 M | Nov 12, 2026 |
| 44 | Osaic Holdings, Inc. | 5,045 | +45 (+0.90%) | 0.01% | $0 M | Nov 12, 2026 |
| 45 | Royal Bank Of Canada | 4,575 | -3,601 (-44.04%) | 0.01% | $0 M | Nov 16, 2026 |
| 46 | Nisa Investment Advisors, LLC | 4,218 | 0 (0.00%) | 0.01% | $0 M | Oct 20, 2026 |
| 47 | PNC Financial Services Group, Inc. | 4,131 | -1,001 (-19.51%) | 0.01% | $0 M | Nov 6, 2026 |
| 48 | Federation des caisses Desjardins du Quebec | 3,000 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 49 | Russell Investments Group, Ltd. | 2,831 | +335 (+13.42%) | 0.01% | $0 M | Nov 6, 2026 |
| 50 | SBI Securities Co., Ltd. | 2,451 | +1,320 (+116.71%) | 0.01% | $0 M | Oct 22, 2026 |
| 51 | Ameritas Advisory Services, LLC | 2,000 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 52 | Bollard Group LLC | 1,570 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 53 | Group One Trading LLC | 1,409 | -100 (-6.63%) | 0.00% | $0 M | Nov 10, 2026 |
| 54 | EverSource Wealth Advisors, LLC | 1,018 | -1,561 (-60.53%) | 0.00% | $0 M | Nov 4, 2026 |
| 55 | BNP Paribas Financial Markets | 884 | -138,310 (-99.36%) | 0.00% | $0 M | Nov 12, 2026 |
| 56 | Essential Partners LLC | 639 | -1,136 (-64.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 57 | NewEdge Advisors, LLC | 547 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 58 | Allworth Financial LP | 370 | -2,214 (-85.68%) | 0.00% | $0 M | Nov 17, 2026 |
| 59 | Jones Financial Companies Lllp | 200 | New | 0.00% | $0 M | Nov 13, 2026 |
| 60 | GAMMA Investing LLC | 152 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 61 | True Wealth Design, LLC | 98 | -380 (-79.50%) | 0.00% | $0 M | Oct 13, 2026 |
| 62 | IFP Advisors, Inc | 67 | -96 (-58.90%) | 0.00% | $0 M | Oct 16, 2026 |
| 63 | Nuveen, LLC | 57 | -10,172 (-99.44%) | 0.00% | $0 M | Nov 10, 2026 |
| 64 | Rothschild Investment LLC | 33 | -541 (-94.25%) | 0.00% | $0 M | Nov 10, 2026 |
| 65 | Farther Finance Advisors, LLC | 8 | -436 (-98.20%) | 0.00% | $0 M | Oct 8, 2026 |
| 66 | Caitong International Asset Management Co., Ltd | 5 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Myomo, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.24 M | $1 M | 3.1% | <0.01% | +47% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 372,587 | $0 M | 0.93% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 219,059 | $0 M | 0.55% | <0.01% | +24% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 180,461 | $0 M | 0.45% | <0.01% | +4.1% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 47,667 | $0 M | 0.12% | <0.01% | +16% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 45,583 | $0 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 31,752 | $0 M | 0.08% | <0.01% | +3.3% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 21,739 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 13,237 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 10,229 | $0 M | 0.03% | <0.01% | −94% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 6,508 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1,694 | $0 M | <0.01% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,334 | $0 M | <0.01% | <0.01% | −39% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,324 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 203 | $0 M | <0.01% | <0.01% | +18% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 15 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Myomo, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David A. HenryChief Financial Officer | Grant or award | +51,250 | — | — | 549,862 | Form 4 |
| filed | Paul R. GudonisChief Executive Officer, Director | Grant or award | +71,250 | — | — | 1.51 M | Form 4 |
| filed | Harry KovelmanChief Medical Officer | Grant or award | +32,500 | — | — | 122,389 | Form 4 |
| filed | Mary-Katherine Hale McClureChief Commericial Officer | Grant or award | +275,000 | — | — | 275,000 | Form 4 |
| filed | David A. HenryChief Financial Officer | Shares withheld for tax | -3,133 | $1.370 | $4 K | 498,612 | Form 4 |
| filed | Paul R. GudonisChief Executive Officer, Director | Grant or award | +8,363 | — | — | 1.44 M | Form 4 |
| filed | David A. HenryChief Financial Officer | Grant or award | +6,272 | — | — | 501,745 | Form 4 |
| filed | Harry KovelmanChief Medical Officer | Sellamended | -15,844 | $1.271 | $20 K | 89,889 | Form 4/A |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Myomo, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-16 reverse split
Fails to deliver
- : 12,663 shares at $1.17
- : 12,920 shares at $1.21
- : 178 shares at $1.26
- : 7,920 shares at $1.45
- : 2,782 shares at $1.57
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Myomo, Inc. scorecard#
Passes 9 of the 22 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median4.1×Price to book 4.1× against Medical Devices's median of 2.5×.
- ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%-34.6%Free cash flow is -34.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year25.8%Revenue up 25.8% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years38.0%38.0% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median38.0%38.0% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-0.37 vs -0.16Diluted EPS -0.37 in fiscal 2025 against -0.16 the year before (report's currency).
- ✗Net income higher than five years earlier-$16 M-$16 M in fiscal 2025 against -$12 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$16 MNet income -$16 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-35.2%-35.2% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-86.2%-86.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-35.2%-35.2% in fiscal 2025 against -68.6% in 2022.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities3.3×Current ratio 3.30 at the end of fiscal 2025.
- ✓Debt below equity1.0×Debt to equity 0.98 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $3 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-2.84Z-score -2.84 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year10.8%Diluted shares up 10.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Myomo, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -35.2% | -8.2% | |
| Net margin | -38.0% | -10.4% | |
| Return on equity | -86.2% | -16.8% | |
| Revenue growth, 3 years a year | 38.0% | 10.8% | |
| Revenue growth | 25.8% | 10.4% | |
| Debt to equity | 0.98× | 0.64× |
3of 9on the Piotroski tests of financial strength
- Net loss of $16 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$16 million.
- The share count rose 10.8% in the year.
- Revenue has grown 9 years in a row.
Myomo, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 41+25.7%100% | 33+69.2%100% | 19+23.7%100% | 16+12.3%100% | 14+82.7%100% | 7.6+97.6%100% | 3.8+57.0%100% | 2.4+56.8%100% | 1.6+41.3%100% | 1.1—100% | |
| Cost of revenue | 14+49.9%34.3% | 9.4+54.6%28.8% | 6.1+14.3%31.5% | 5.3+49.6%34.1% | 3.5+36.3%25.6% | 2.6+83.0%34.3% | 1.4r0.9+95.1%37.0% | 0.7+44.1%29.8% | 0.5+79.1%32.4% | 0.3—25.6% | |
| Gross profit | 27+16.0%65.7% | 23+75.9%71.2% | 13+28.6%68.5% | 10−0.6%65.9% | 10+107%74.4% | 5.0+106%65.7% | 2.4r2.9+40.9%63.0% | 1.7+62.9%70.2% | 1.1+28.3%67.6% | 0.8—74.4% | |
| Research and development | 6.9+45.5%17.0% | 4.8+81.0%14.7% | 2.6+6.2%13.7% | 2.5−2.9%16.0% | 2.6+53.2%18.5% | 1.7−4.6%22.0% | 1.7r2.2−4.8%45.6% | 1.8+5.0%75.2% | 1.8+56.3%112% | 1.1—102% | |
| Selling, general and administrative | — | — | 19+1.8%97.6% | 18+2.3%119% | 18+30.4%130% | 14+20.5%182% | 11r12+10.2%299% | 10+77.9%426% | 5.8+96.6%375% | 3.0—270% | |
| Selling and marketing | 20+66.6%49.8% | 12+35.3%37.6% | 9.0—47.0% | — | — | — | — | — | — | — | |
| General and administrative | 14+12.7%34.1% | 12+27.2%38.0% | 9.7—50.6% | — | — | — | — | — | — | — | |
| Operating expenses | 41+40.5%101% | 29+37.3%90.3% | 21+2.3%111% | 21+1.7%135% | 21+32.9%149% | 15+17.2%204% | 13r14+7.9%344% | 12+61.1%501% | 7.6+85.6%488% | 4.1—371% | |
| Operating income | −14—−35.2% | −6.2—−19.1% | −8.2—−42.8% | −11—−68.6% | −10—−74.1% | −11—−138% | −11—−281% | −11—−431% | −6.5—−420% | −3.3—−297% | |
| Interest expense and finance costs | — | — | — | — | — | 0.2+92.6%2.9% | 0.1—3.0% | — | — | — | |
| Other non-operating income (expense) | −0.7−272%−1.6% | 0.4+61.9%1.2% | 0.2+1036%1.2% | 0.0—0.1% | −0.0—−0.1% | −1.1−1394%−14.0% | 0.1−61.3%2.1% | 0.2—8.7% | −5.5—−356% | −0.3—−31.0% | |
| Income before tax | −15—−36.8% | −5.8—−17.9% | −8.0—−41.5% | −11—−68.5% | −10—−74.2% | −12—−152% | — | — | — | — | |
| Income tax | 0.5+38.0%1.2% | 0.4+134%1.1% | 0.2+123%0.8% | 0.1−21.4%0.4% | 0.1—0.6% | — | — | — | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −16—−38.1% | −6.2—−19.0% | −8.1—−42.3% | −11—−68.9% | −10—−74.9% | −12—−152% | −11—−279% | −10—−422% | −12—−776% | — | |
| Minority interests' share of net income | — | — | — | — | — | — | −12—−300% | — | — | — | |
| Net income attributable to shareholders | −16—−38.1% | −6.2—−19.0% | −8.1—−42.3% | −11—−68.9% | −10—−74.9% | −12—−152% | −11—−279% | −10—−422% | −12—−776% | −3.6—−328% | |
| Earnings per share, basic | -0.37—— | -0.16—— | -0.28—— | -1.52—— | -1.89—— | -3.67—— | -20.79r-19.35—— | -25.18r-0.84—— | -2.93—— | -4.13—— | |
| Earnings per share, diluted | -0.37—— | -0.16—— | -0.28—— | -1.52—— | -1.89—— | -3.67—— | -20.79r-19.35—— | -25.18r-0.84—— | -2.93—— | -4.13—— | |
| Shares, weighted average (basic) | 42+10.8%— | 38+28.0%— | 29+318%— | 7.1+20.9%— | 5.8—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 42+10.8%— | 38+28.0%— | 29+318%— | 7.1+20.9%— | 5.8+75.1%— | 3.3+501%— | 0.6+35.2%— | 0.4r12−90.5%— | 4.3+307%— | 1.1—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 14−42.0%36.6% | 24+255%57.7% | 6.9+28.5%47.1% | 5.3−65.6%52.6% | 16+26.8%77.3% | 12+174%83.2% | 4.5−31.7%67.7% | 6.5−49.5%79.0% | 13+1526%92.7% | 0.8—48.1% | |
| Short-term investments | 4.3+764%11.0% | 0.5−75.3%1.2% | 2.0—13.7% | 0—0.0% | — | — | — | — | — | — | |
| Receivables | 4.1+7.1%10.6% | 3.8+60.5%9.1% | 2.4+25.7%16.3% | 1.9−3.3%18.7% | 2.0+112%9.8% | 0.9+118%6.3% | 0.4+11.0%6.4% | 0.4+28.7%4.6% | 0.3+159%2.1% | 0.1—6.9% | |
| Inventory | 3.1−1.4%8.1% | 3.2+75.5%7.5% | 1.8+28.8%12.4% | 1.4+73.2%13.8% | 0.8+14.3%4.0% | 0.7+60.9%4.8% | 0.4+71.6%6.7% | 0.3+27.3%3.1% | 0.2+144%1.4% | 0.1—5.0% | |
| Other current assets | 1.9+108%5.0% | 0.9+55.9%2.2% | 0.6+4.4%4.1% | 0.6−28.2%5.6% | 0.8r0.9+39.5%4.0% | 0.6−30.2%3.9% | 0.8+18.0%12.4% | 0.7+79.1%8.4% | 0.4+155%2.8% | 0.2—9.2% | |
| Current assets | 28−16.0%71.3% | 33+140%77.6% | 14+48.1%93.6% | 9.2−51.7%90.7% | 19r19+32.2%95.0% | 14+135%98.2% | 6.1−21.9%93.2% | 7.9−43.1%95.1% | 14+1108%99.1% | 1.1—69.1% | |
| Property, plant and equipment | 2.2+66.4%5.7% | 1.3+657%3.1% | 0.2−9.5%1.2% | 0.2−29.4%1.9% | 0.3+190%1.4% | 0.1−38.7%0.6% | 0.2−17.4%2.3% | 0.2+143%2.3% | 0.1+258%0.6% | 0.0—1.3% | |
| Right-of-use (leased) assets | 6.7−11.9%17.3% | 7.6+1043%18.0% | 0.7+30.4%4.6% | 0.5−19.6%5.0% | 0.6+275%3.1% | 0.2—1.1% | — | — | — | — | |
| Total assets | 39−8.5%100% | 42+190%100% | 15+43.5%100% | 10−49.4%100% | 20+36.6%100% | 15+123%100% | 6.6−20.3%100% | 8.3−40.7%100% | 14+743%100% | 1.7—100% | |
| Accounts payable | 1.1r1.5−5.9%2.9% | 1.2+9.0%2.8% | 1.1+88.4%7.4% | 0.6−21.2%5.6% | 0.7+301%3.6% | 0.2−59.9%1.2% | 0.5+5.5%6.8% | 0.4+61.1%5.2% | 0.3−14.8%1.9% | 0.3—18.8% | |
| Debt due within a year | 0r3.0−100%0.0% | 3.0r0—7.0% | — | — | — | — | 1.8—26.7% | — | — | — | |
| Current liabilities | 8.3−18.0%21.6% | 10+85.7%24.1% | 5.5+52.1%37.6% | 3.6−15.9%35.4% | 4.3+49.3%21.3% | 2.9−26.1%19.5% | 3.9+109%58.9% | 1.9+24.9%22.4% | 1.5−50.5%10.6% | 3.0—181% | |
| Long-term debt | — | — | — | — | — | — | 0.9—13.5% | — | — | — | |
| Lease liabilities (non-current) | 7.7+4.2%19.8% | 7.4+6290%17.4% | 0.1−42.5%0.8% | 0.2−50.2%2.0% | 0.4+159%2.0% | 0.2—1.1% | — | — | — | — | |
| Non-current liabilities | — | — | — | — | — | — | — | — | — | 3.5—212% | |
| Total liabilities | 27+55.4%70.5% | 18+213%41.5% | 5.6+47.1%38.4% | 3.8−18.9%37.4% | 4.7+49.0%23.3% | 3.1−34.1%21.4% | 4.8+157%72.3% | 1.9+21.3%22.4% | 1.5−76.5%10.9% | 6.5—393% | |
| Retained earnings | −119—−307% | −103—−244% | −97—−665% | −89—−874% | −78—−388% | −68—−460% | −56—−851% | −45—−547% | −35—−250% | −23—−1379% | |
| Shareholders' equity | 11−53.9%29.5% | 25+175%58.5% | 9.0+41.4%61.6% | 6.4−58.7%62.6% | 15+33.2%76.7% | 12+80.0%78.6% | 6.4r1.80.0%97.4% | 6.4−48.4%77.6% | 12—89.1% | −18—−1057% | |
| Total liabilities and equity | 39−8.5%100% | 42+190%100% | 15+43.5%100% | 10−49.4%100% | 20+36.6%100% | 15+123%100% | 6.6−20.3%100% | 8.3−40.7%100% | 14+743%100% | 1.7—100% | |
| Shares outstanding | 38+11.9%— | 34r34+26.7%— | 27+250%— | 7.8+12.8%— | 6.9+49.6%— | 4.6+700%— | 0.6+38.4%— | 0.4r12−96.3%— | 11+891%— | 1.1—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 2.1+138%5.1% | 0.9−21.6%2.7% | 1.1−6.3%5.8% | 1.2+8.6%7.7% | 1.1+78.5%7.9% | 0.6−32.3%8.1% | 0.9+11.5%23.7% | 0.8+191%33.3% | 0.3+197%17.9% | 0.1—8.5% | |
| Cash from operating activities | −15—−35.5% | −3.3—−10.1% | −6.2—−32.1% | −10—−65.8% | −9.5—−68.9% | −9.0—−119% | −10—−269% | −9.6—−393% | −6.2—−395% | −3.2—−290% | |
| Capital expenditure | −1.7—−4.3% | −1.4—−4.2% | −0.1—−0.8% | −0.1—−0.7% | −0.3—−2.4% | −0.0—−0.6% | −0.1—−1.4% | −0.1—−5.2% | −0.1—−4.3% | −0.0—−0.2% | |
| Cash from investing activities | −7.1−2815%−17.2% | 0.3—0.8% | −2.0—−10.5% | −0.3—−2.0% | −0.3—−2.4% | −0.0—−0.6% | −0.1—−1.4% | −0.1—−5.2% | −0.1—−4.3% | −0.0—−0.2% | |
| Debt issued | 3.0—7.3% | 0—0.0% | — | — | — | — | 2.8—72.6% | — | — | — | |
| Debt repaid | −4.0—−9.8% | 0—0.0% | — | — | — | −1.7—−22.5% | — | — | — | — | |
| Shares issued | — | — | — | — | 1.1—7.9% | — | — | — | 10—668% | — | |
| Cash from financing activities | 11−45.4%27.9% | 21+115%64.3% | 9.7+2477%50.5% | 0.4−97.1%2.4% | 13−21.5%95.0% | 17+102%221% | 8.3+149%217% | 3.3−81.8%137% | 18+521%1179% | 3.0—268% | |
| Change in cash | −10−156%−24.5% | 18+1072%54.9% | 1.5—7.9% | −10−410%−65.4% | 3.3−57.4%23.7% | 7.7—102% | −2.1—−54.1% | −6.4−153%−262% | 12—780% | −0.2—−22.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 46+9.3%100% | 12+22.2%100% | 12+21.3%100% | 10+2.9%100% | 11*−5.9%100% | 10+9.6%100% | 9.7+28.3%100% | 9.8+162%100% | 12*+154%100% | 9.2—100% | 7.5—100% | 3.8—100% | 4.8*—100% | |
| Cost of revenue | 14−2.4%29.9% | 3.5−3.0%28.7% | 3.3−9.4%27.9% | 3.2−0.3%31.8% | 3.6*+3.4%31.4% | 3.6+61.3%36.2% | 3.6+64.0%37.3% | 3.2+121%32.8% | 3.5*+109%28.6% | 2.3—24.6% | 2.2—29.2% | 1.5—38.8% | 1.7r1.7*—34.7% | |
| Gross profit | 32+15.1%70.1% | 8.8+36.4%71.3% | 8.4+39.5%72.1% | 6.9+4.4%68.2% | 7.8*−9.6%68.6% | 6.4−7.2%63.8% | 6.1+13.6%62.7% | 6.6+187%67.2% | 8.6*+177%71.4% | 6.9—75.4% | 5.3—70.8% | 2.3—61.2% | 3.1*—65.3% | |
| Research and development | 6.8−1.5%14.9% | 1.8+18.5%14.7% | 1.7−14.0%14.7% | 1.6−9.3%16.0% | 1.6*+4.2%14.3% | 1.5+22.3%15.1% | 2.0+98.7%20.7% | 1.8+87.2%18.2% | 1.6*+77.6%12.9% | 1.2—13.6% | 1.0—13.4% | 1.0—25.5% | 0.9r0.9*—18.5% | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | — | — | — | 4.7*—98.0% | |
| Selling and marketing | 21+11.4%45.5% | 5.1−2.6%41.5% | 5.3+0.6%45.0% | 4.8+9.6%47.6% | 5.5*+48.8%48.5% | 5.3+54.5%52.1% | 5.2+88.5%54.2% | 4.4+86.1%44.7% | 3.7*+57.1%30.6% | 3.4—36.9% | 2.8—36.9% | 2.4—62.9% | 2.4*—49.5% | |
| General and administrative | 14+1.5%31.5% | 3.6+12.8%29.1% | 3.7+9.0%31.7% | 3.6−8.2%35.8% | 3.4*−4.8%30.2% | 3.2−2.3%31.5% | 3.4+28.3%35.3% | 3.9+37.4%40.1% | 3.6*+56.2%29.9% | 3.3—35.3% | 2.7—35.3% | 2.9—76.4% | 2.3*—48.5% | |
| Operating expenses | 42+5.6%91.9% | 11+5.6%85.3% | 11+0.5%91.4% | 10−0.7%99.5% | 11*+19.2%93.0% | 10.0+26.0%98.7% | 11+65.2%110% | 10+63.7%103% | 8.9*+60.0%73.4% | 7.9—85.8% | 6.4—85.6% | 6.2—165% | 5.5r5.5*—116% | |
| Operating income | −9.9—−21.8% | −1.7—−14.0% | −2.3—−19.3% | −3.2—−31.2% | −2.8*—−24.4% | −3.5—−34.9% | −4.6—−47.6% | −3.5—−35.8% | −0.2*—−2.0% | −1.0—−10.4% | −1.1—−14.8% | −3.9—−104% | −2.4r−2.4*—−51.2% | |
| Other non-operating income (expense) | −4.8−1427%−10.5% | −2.4—−19.5% | −1.7−1729%−14.8% | 0.3+74.2%3.3% | −1.0*−1466%−8.4% | −0.0−113%−0.1% | 0.1−0.6%1.1% | 0.2+41.9%2.0% | 0.1*+59.6%0.6% | 0.1—0.8% | 0.1—1.4% | 0.1—3.6% | 0.0*—0.9% | |
| Income before tax | −15—−32.2% | −4.1—−33.5% | −4.0—−34.1% | −2.8—−27.9% | −3.7*—−32.9% | −3.5—−35.0% | −4.5—−46.5% | −3.3—−33.9% | −0.2*—−1.5% | −0.9—−9.6% | −1.0—−13.4% | −3.8—−100.0% | −2.4*—−50.2% | |
| Income tax | 0.4−19.7%0.9% | 0.1−23.4%0.8% | 0.0−78.8%0.3% | 0.2+36.5%1.8% | 0.1*−1.1%0.7% | 0.1+59.8%1.3% | 0.1+30.2%1.5% | 0.1+66.5%1.4% | 0.1*+19.8%0.7% | 0.1—0.9% | 0.1—1.5% | 0.1—2.2% | 0.1*—1.5% | |
| Net income including minority interests | −15—−33.1% | −4.2*—−34.3% | −4.0*—−34.4% | −3.0—−29.8% | −3.8*—−33.6% | −3.7*—−36.3% | −4.6*—−48.0% | −3.5—−35.2% | −0.3*—−2.2% | −1.0*—−10.5% | −1.1*—−14.9% | −3.8—−102% | −2.5*—−51.7% | |
| Net income attributable to shareholders | −15—−33.1% | −4.2—−34.3% | −4.0—−34.4% | −3.0—−29.8% | −3.8*—−33.6% | −3.7—−36.3% | −4.6—−48.0% | −3.5—−35.2% | −0.3*—−2.2% | −1.0—−10.5% | −1.1—−14.9% | −3.8—−102% | −2.5*—−51.7% | |
| Earnings per share, basic | — | -0.10—— | -0.09—— | -0.07—— | — | -0.09—— | -0.11—— | -0.08—— | — | -0.03—— | -0.03—— | -0.10—— | — | |
| Earnings per share, diluted | — | -0.10—— | -0.09—— | -0.07—— | — | -0.09—— | -0.11—— | -0.08—— | — | -0.03—— | -0.03—— | -0.10—— | — | |
| Shares, weighted average (basic) | 44+3.3%— | 44+3.3%— | 43+2.7%— | 42+2.0%— | — | 42+11.1%— | 42+11.3%— | 41+12.8%— | — | 38—— | 37—— | 37—— | — | |
| Shares, weighted average (diluted) | 44+3.3%— | 44+3.3%— | 43+2.7%— | 42+2.0%— | — | 42+11.1%— | 42+11.3%— | 41+12.8%— | — | 38—— | 37—— | 37—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 11—32.8% | 11−11.6%32.8% | 11−21.2%31.7% | 11−42.4%31.0% | 14−42.0%36.6% | 13+89.6%36.8% | 14+144%36.8% | 20+264%48.4% | 24+255%57.7% | 6.6—40.6% | 5.8—36.1% | 5.4—32.9% | 6.9—47.1% | |
| Short-term investments | 0.8—2.5% | 0.8—2.5% | 2.2+79.9%6.3% | 4.30.0%11.7% | 4.3+764%11.0% | 0—0.0% | 1.2−60.4%3.2% | 4.3r1.7−22.2%10.5% | 0.5−75.3%1.2% | 0—0.0% | 3.1—19.4% | 5.5—33.4% | 2.0—13.7% | |
| Receivables | 5.9—17.5% | 5.9+11.9%17.5% | 4.9−29.9%14.0% | 4.8+3.5%13.1% | 4.1+7.1%10.6% | 5.3+41.9%15.5% | 7.1+179%18.2% | 4.7+177%11.4% | 3.8+60.5%9.1% | 3.7—22.9% | 2.5—15.6% | 1.7—10.2% | 2.4—16.3% | |
| Inventory | 3.1—9.2% | 3.1−15.1%9.2% | 3.2−23.2%9.0% | 3.5+5.3%9.7% | 3.1−1.4%8.1% | 3.6+7.7%10.7% | 4.1+58.6%10.7% | 3.4+41.1%8.2% | 3.2+75.5%7.5% | 3.4—20.7% | 2.6—16.1% | 2.4—14.4% | 1.8—12.4% | |
| Other current assets | 2.5—7.5% | 2.5+73.9%7.5% | 3.0+114%8.4% | 1.6+3.1%4.3% | 1.9+108%5.0% | 1.5+50.5%4.3% | 1.4+33.8%3.6% | 1.5+128%3.8% | 0.9+55.9%2.2% | 1.0—5.9% | 1.0—6.4% | 0.7—4.1% | 0.6—4.1% | |
| Current assets | 23—69.5% | 23+2.4%69.5% | 25−12.5%69.4% | 26−17.5%69.8% | 28−16.0%71.3% | 23+56.1%67.3% | 28+85.2%72.5% | 31+98.0%76.1% | 33+140%77.6% | 15—90.1% | 15—93.5% | 16—95.1% | 14—93.6% | |
| Property, plant and equipment | 1.7—5.1% | 1.7−53.3%5.1% | 2.0−31.7%5.6% | 2.2+21.7%6.1% | 2.2+66.4%5.7% | 3.7+562%10.9% | 2.9+905%7.5% | 1.8+795%4.5% | 1.3+657%3.1% | 0.6—3.4% | 0.3—1.8% | 0.2—1.2% | 0.2—1.2% | |
| Right-of-use (leased) assets | 6.3—18.7% | 6.3−7.9%18.7% | 6.5−7.7%18.4% | 6.5−10.9%17.7% | 6.7−11.9%17.3% | 6.9+1371%20.2% | 7.1+1208%18.3% | 7.3+1106%17.9% | 7.6+1043%18.0% | 0.5—2.9% | 0.5—3.3% | 0.6—3.7% | 0.7—4.6% | |
| Total assets | 34—100% | 34−0.8%100% | 35−8.6%100% | 37−10.1%100% | 39−8.5%100% | 34+109%100% | 39+139%100% | 41+147%100% | 42+190%100% | 16—100% | 16—100% | 17—100% | 15—100% | |
| Accounts payable | 1.1—3.3% | 1.1−31.9%3.3% | 1.2−50.5%3.5% | 1.8−27.2%4.9% | 1.1r1.5−5.9%2.9% | 1.6+24.8%4.8% | 2.5+83.6%6.5% | 2.5+200%6.1% | 1.2+9.0%2.8% | 1.3—8.0% | 1.4—8.5% | 0.8—5.0% | 1.1—7.4% | |
| Debt due within a year | 1.8—5.3% | 1.8+206%5.3% | 0.4+168%1.3% | 2.7—7.4% | 0r3.0−100%0.0% | 0.6—1.7% | 0.2—0.4% | — | 3.0r0—7.0% | — | — | — | — | |
| Current liabilities | 12—36.3% | 12+33.3%36.3% | 11−9.7%30.0% | 9.4−19.6%25.5% | 8.3−18.0%21.6% | 9.2+31.6%27.0% | 12+81.8%30.4% | 12+110%28.6% | 10+85.7%24.1% | 7.0—42.9% | 6.5—39.9% | 5.6—33.6% | 5.5—37.6% | |
| Lease liabilities (non-current) | 7.0—20.6% | 7.0−11.1%20.6% | 7.2−9.6%20.4% | 7.4−0.9%20.2% | 7.7+4.2%19.8% | 7.8+26757%23.0% | 8.0+16737%20.6% | 7.5+11518%18.4% | 7.4+6290%17.4% | 0.0—0.2% | 0.0—0.3% | 0.1—0.4% | 0.1—0.8% | |
| Total liabilities | 31—91.9% | 31+59.6%91.9% | 30+40.2%83.5% | 28+44.7%75.5% | 27+55.4%70.5% | 19+177%57.1% | 21+223%54.5% | 19+241%46.9% | 18+213%41.5% | 7.0—43.0% | 6.5—40.2% | 5.6—34.0% | 5.6—38.4% | |
| Retained earnings | −130—−384% | −130—−384% | −126—−356% | −122—−331% | −119—−307% | −115—−337% | −111—−288% | −107—−261% | −103—−244% | −103—−631% | −102—−629% | −101—−610% | −97—−665% | |
| Shareholders' equity | 2.8—8.1% | 2.8−81.2%8.1% | 5.8−66.9%16.5% | 9.0−58.5%24.5% | 11−53.9%29.5% | 15+57.4%42.9% | 18+82.0%45.5% | 22+99.0%53.1% | 25+175%58.5% | 9.3—57.0% | 9.7—59.8% | 11—66.0% | 9.0—61.6% | |
| Total liabilities and equity | 34—100% | 34−0.8%100% | 35−8.6%100% | 37−10.1%100% | 39−8.5%100% | 34+109%100% | 39+139%100% | 41+147%100% | 42+190%100% | 16—100% | 16—100% | 17—100% | 15—100% | |
| Shares outstanding | 40—— | 40+4.2%— | 40+4.6%— | 39+12.0%— | 38+11.9%— | 38+27.1%— | 38+25.1%— | 34+19.6%— | 34r34+26.7%— | 30—— | 30—— | 29—— | 27—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | 0.4*+64.3%3.3% | 0.4*+102%3.3% | 0.3+84.0%2.9% | — | 0.2*—2.4% | 0.2*—2.0% | 0.2—1.6% | — | — | — | — | — | |
| Share-based compensation | 3.5+91.3%7.7% | 1.3+125%10.7% | 1.0+164%8.9% | 0.6+10.6%5.9% | 0.6*+75.5%5.0% | 0.6+80.1%5.8% | 0.4—4.1% | 0.5+68.7%5.5% | 0.3*−3.7%2.7% | 0.3—3.5% | −0.1—−1.2% | 0.3—8.5% | 0.3*—7.0% | |
| Cash from operating activities | −6.6—−14.5% | −1.3*—−10.6% | −1.9*—−16.6% | −2.2—−21.7% | −1.1*−134%−10.0% | −1.8*—−18.1% | −8.9*—−91.8% | −2.7—−27.2% | 3.4*—27.9% | −1.5*—−16.2% | −1.9*—−25.5% | −3.2—−86.4% | −2.4r−2.4*—−49.5% | |
| Capital expenditure | — | −0.1*—−0.4% | −0.0*—−0.3% | −0.3—−3.2% | — | −1.1r−1.1*—−10.4% | −0.2r−1.3*—−2.3% | −0.7—−6.8% | −0.9*—−7.1% | −0.3*—−3.5% | −0.1*—−1.6% | −0.1—−1.6% | −0.0*—−0.7% | |
| Cash from investing activities | −1.7—−3.8% | 1.3*+596%10.7% | 2.0*—17.3% | −0.5—−4.9% | −4.6*—−40.5% | 0.2*−93.3%1.9% | −0.8*−132%−7.8% | −1.9—−19.3% | −1.4*−159%−11.2% | 2.8*—30.7% | 2.3*—31.0% | −3.5—−94.4% | 2.3*—48.2% | |
| Debt issued | — | 0*—0.0% | — | — | −1.0r0*—−8.8% | 0r−1.0*—0.0% | — | — | 0*—0.0% | 0*—0.0% | — | — | — | |
| Cash from financing activities | 7.1−63.7%15.7% | −0.1*—−1.0% | −0.2*−106%−2.1% | 0—0.0% | 7.5*−52.4%66.2% | −0.1*—−0.5% | 4.0*—41.4% | −0.0−101%−0.4% | 16*+50870932%131% | −0.2*—−2.2% | 0*—0.0% | 5.4—143% | 0.0*—0.0% | |
| Change in cash | −1.3−121%−2.8% | −0.1*—−1.0% | −0.2*—−1.5% | −2.7—−27.0% | 1.8*−90.0%15.7% | −1.7*−246%−16.7% | −5.6*−1450%−57.5% | −4.6—−46.6% | 18*—147% | 1.2*—12.5% | 0.4*—5.5% | −1.4—−38.3% | −0.0*—−0.9% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Myomo, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇩🇪 Germany | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Myomo, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Paul Gudonis | $1.2 M | −$349 K | $649 K | $178 |
| 2024Paul Gudonis | $1.2 M | $1.5 M | $740 K | $1259 |
| 2023Paul Gudonis | $664 K | $2.1 M | $479 K | $980 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Myomo, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Auditor changed 1 · Debt called early 1 · Directors and officers 6 · Material agreement 5 · New debt 3 · Unregistered share sale 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K/A | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debtUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Auditor changedDirectors and officers | 8-K | |
| Results announced | 8-K | |
| Debt called earlyMaterial agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Myomo, Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2022.
Lobbying firms hired in 2022
A10 Associates, LLC
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $0 | — | 3 |
| 2021 | $0 | — | 4 |
| 2020 | $240 K | — | 4 |
| 2019 | $332 K | — | 11 |
| 2018 | $80 K | — | 5 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Myomo, Inc.” and “A10 Associates on behalf of Myomo, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Myomo, Inc. compares in Medical Devices
- Market cap$47 M · higher than 25% of 142
- Revenue$41 M · higher than 26% of 155
- Net margin-33.1% · higher than 31% of 144
- Revenue growth25.8% · higher than 79% of 104
- Price / sales1.0× · lower than 81% of 96
- Price / book4.1× · lower than 36% of 99
- FCF yield-34.6% · higher than 21% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Myomo, Inc.🇺🇸 | $47 M | — | -33.1% | +25.8% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Myomo, Inc.? Verify and update this profile — free
Show Myomo, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.